Biorem Reports Second Quarter Results

GUELPH, ON, Aug. 24, 2012 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results for the three-month period ended June 30, 2012.  Biorem's complete 2012 second quarter financial statements and MD&A have been filed on SEDAR (

Financial Summary:

  Three-months ended
June 30,
Six-months ended
June 30,
(in thousands of Canadian dollars, except percent and per share data) 2012 2011 2012 2011
REVENUE $2,873 $3,902 $6,140 $7,634
RESULTS FROM OPERATING ACTIVITIES $(615) $(415) $(1,098) $(322)
NET EARNINGS/(LOSS) $(680) $(496) $(1,224) $(516)

Revenues for the three months ended June 30, 2012 were $2.8 million compared to $3.3 million recorded the previous quarter, and $3.9 million in the similar period in the prior year. Six month revenues to June 30 totaled $6.1 million, a $1.5 million decrease from $7.6 million in revenues for the six months ended June 30, 2011.

Gross profit for the quarter was $490,000 representing 17% of revenues, a $110,000 improvement over the $380,000 of gross profit and 11.7% of revenues in realized in Q1 2012.

The Company recorded a net loss for the quarter of $680,000 representing a loss of $0.05 per share. The net loss for the six months ended June 30, 2012 was $1,224,000, a loss per share of $0.09.

The Company's backlog of orders at June 30, 2012 stood at $13.6 million, a $1.6 million improvement over the order back log at June 30, 2011.  However, as at August 21, 2012 this backlog had grown to $17.5 million.

As previously announced, during Q2 2012 the Company issued convertible secured debentures for gross proceeds of $659,000.

Subsequent to June 30, 2012 the Company improved its working capital position by issuing additional convertible secured debentures for gross proceeds of $1.1 million and received $500,000 in additional debt financing through an amending agreement with the existing lender of a 12.75 % debenture.

"Due to our strained working capital situation that had developed through the first and into the second quarters we anticipated a significant slowdown in shipments from our vendors in the quarter" said Peter Bruijns, President and CEO. "With the two capital raises, plus the incremental debt the company has added $2,272,000 of working capital which has enabled shipments to resume in Q3.  With our high current backlog and improving project margins we anticipate improved performance from the company through the remainder of 2012."

About BIOREM Inc.
Biorem is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). With sales and manufacturing offices across the continent, a dedicated research facility, a worldwide sales representative network and more than 700 installed systems worldwide, Biorem offers state-of-the-art technology-based products and peace of mind for municipalities, industrial companies and their surrounding communities. Additional information on Biorem is available on our website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This press release contains forward-looking statements based on current expectations. These forward-looking statements contain various risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Risks and uncertainties about the Company's business are more fully discussed in the disclosure materials, financial statements and MD&A filed with the securities regulatory authorities in Canada on

Order Bookings and Order Backlog are non-IFRS measures that the Company uses to evaluate its sales performance. Order Bookings are those binding contracts that the Company enters into with a third party for the delivery of our products or services. As Order Bookings are received, the contract value (before any associated sales taxes) is included in the Order Backlog. The Order Backlog is reduced by the revenue that is recognized on each project and then adjusted for any currency changes.

SOURCE Biorem Inc.

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.